The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TCRX | -46.15% | N/A | N/A | -89% |
| S&P | +17.45% | +75.43% | +11.88% | +56% |
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
No news articles found for TScan Therapeutics.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.57M | 286.0% |
| Gross Profit | $1.84M | 4108.7% |
| Gross Margin | 71.83% | 78.8% |
| Market Cap | $56.75M | -65.0% |
| Market Cap / Employee | $399.63K | 0.0% |
| Employees | 142 | -26.8% |
| Net Income | -$22,977.00K | 35.8% |
| EBITDA | -$23,135.00K | 35.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $152.41M | -14.7% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $86.97M | -6.3% |
| Short Term Debt | $7.17M | 56.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -43.26% | -3.6% |
| Return On Invested Capital | -50.84% | -1.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$32,173.00K | -13.7% |
| Operating Free Cash Flow | -$32,002.00K | -16.7% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.32 | 0.39 | 0.58 | 0.39 | -44.35% |
| Price to Sales | 40.48 | 27.02 | 28.05 | 12.58 | -90.35% |
| Price to Tangible Book Value | 0.32 | 0.39 | 0.58 | 0.39 | -44.35% |
| Enterprise Value to EBITDA | -0.68 | -1.76 | -4.06 | -3.09 | -36.14% |
| Return on Equity | -78.9% | -63.3% | -76.4% | -71.3% | 9.53% |
| Total Debt | $97.04M | $96.70M | $95.62M | $94.14M | -3.33% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
